Literature DB >> 34714472

Computed tomography-guided lymphangiography from the para-aortic lymph node: a useful approach for chylothorax after esophagectomy.

Yuta Onikubo1, Shusuke Yagi1, Kazuhiko Yamada2, Daiki Kato1, Hitomi Wake1, Naoki Enomoto1, Kyoko Nohara1, Tsuyoshi Tajima3, Norihiro Kokudo1.   

Abstract

BACKGROUND: Chylothorax is a relatively rare complication of esophagectomy but can lead to fatal conditions. The aim of this report was to present a case of lymphangiography from the para-aortic lymph node (PALN) under computed tomography (CT) guidance, which could be an alternative modality to ultrasound sonography from the groin. CASE
PRESENTATION: A 58-year-old man was diagnosed as having postoperative chylothorax after esophagectomy following neoadjuvant chemotherapy. As the pleural effusion did not improve, intranodal lipiodol lymphangiography from the inguinal lymph node was performed but was unsuccessful. Therefore, CT-guided lymphangiography from the left PALN was performed, and the pleural effusion drainage significantly disappeared.
CONCLUSIONS: CT-guided lipiodol lymphangiography from the PALN for chylothorax after esophagectomy was safe and thus can be considered an alternative treatment option to ultrasonography-guided intranodal lymphangiography. The flexible use of CT and ultrasonography for lymphangiography may improve the treatment outcomes of chylothorax after esophagectomy.
© 2021. The Japanese Association for Thoracic Surgery.

Entities:  

Keywords:  CT-guided; Chylothorax; Esophageal cancer; Lipiodol; Lymphangiography

Mesh:

Year:  2021        PMID: 34714472     DOI: 10.1007/s11748-021-01727-w

Source DB:  PubMed          Journal:  Gen Thorac Cardiovasc Surg        ISSN: 1863-6705


  1 in total

Review 1.  Radiological management of postoperative lymphorrhea.

Authors:  C M Sommer; C C Pieper; F Offensperger; F Pan; H J Killguss; J Köninger; M Loos; T Hackert; M Wortmann; T D Do; G Maleux; G M Richter; H U Kauczor; J Kim; S Hur
Journal:  Langenbecks Arch Surg       Date:  2021-04-12       Impact factor: 3.445

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.